Alkermes plc today presented new research from its psychiatry portfolio at the 2022 Congress of the Schizophrenia International Research Society (SIRS).
The U.S. Food and Drug Administration approved BioXcel Therapeutics Inc.’s IGALMI (dexmedetomidine) sublingual film for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.
Noven Pharmaceuticals won approval from the U.S. Food and Drug Administration for the company’s transdermal schizophrenia patch.
Intra-Cellular Therapies shares fell after the company announced that the FDA canceled the advisory committee meeting to discuss the New Drug Application for the schizophrenia drug lumateperone.
Alkermes Plc said the company’s long-acting injectable therapy for schizophrenia has helped reduce symptoms and can become an effective option for ensuring patients stay on medication even after being discharged from hospital.
Intra-Cellular Therapies Inc. announced that the U.S. Food and Drug Administration accepted for review the biopharmaceutical company’s New Drug Application for lumateperone, an investigational agent for the treatment of schizophrenia.
Med Ad News’ first edition of the Pharma Leaders of Innovation special feature showcases two CEOs focusing outside the big pharma box and an agency tech leader.
Quitting smoking is just about one of the hardest things you can do, but new research suggests there may be yet another serious reason to consider it. The new study in […]
TOKYO & VALBY, Denmark–(BUSINESS WIRE)–Otsuka Pharmaceutical Co., Ltd. (Otsuka) and H. Lundbeck A/S (Lundbeck) announced today that the U.S. Food and Drug Administration (FDA) approved REXULTI® (brexpiprazole) as an adjunctive therapy […]